1. Scrip
  2. >>Business

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

 
• By Jessica Merrill

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 

empty shelves
Generics industry is monitoring the potential for drug shortages • Source: Shutterstock

Part of the fallout from the coronavirus outbreak could be drug shortages caused by active pharmaceutical ingredient manufacturing disruptions in China and other regions. Supply appears stable for now, but shortages could become an issue late in the second quarter or early third quarter if manufacturing disruptions continue longer term, Bernstein Research analyst Ronny Gal concluded in a 26 February research report.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Enzene To Prepone US Capacity Addition Amid Tariff Talk

 
• By Vibha Ravi

Enzene Biosciences is likely to front-load capacity at its new US facility amid an onshoring focus, CEO Himanshu Gadgil tells Scrip. Possible US tariff exemption for Indian pharma products, impact of higher steel and aluminum tariffs on US manufacturing and a change in the company’s biosimilars strategy are discussed in this wide-ranging interview

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

 
• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.

Roche US Exports To Exceed Imports After New $50bn Investment

 
• By Andrew McConaghie

A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Scrip

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

 
• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.